Jacksonville, FLORIDA5 Active Studies

Lupus Clinical Trials in Jacksonville, FLORIDA

Find 5 actively recruiting lupus clinical trials in Jacksonville, FLORIDA. Connect with local research sites and explore new treatment options.

5
Active Trials
4
Sponsors
1,251
Enrolling

Recruiting Lupus Studies in Jacksonville

RecruitingJacksonville, FLORIDANCT05620407

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population....

490 participants
Bristol-Myers Squibb
View Study Details
RecruitingJacksonville, FLORIDANCT05126277

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult p...

420 participants
Novartis Pharmaceuticals
View Study Details
RecruitingJacksonville, FLORIDANCT05268289

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment....

240 participants
Novartis Pharmaceuticals
View Study Details
RecruitingJacksonville, FLORIDANCT07015983

A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate respo...

89 participants
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
View Study Details
RecruitingJacksonville, FLORIDANCT06121297

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus...

12 participants
Cabaletta Bio
View Study Details

About Lupus Clinical Trials in Jacksonville

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect the joints, skin, kidneys, brain, and other organs. It is more common in women and often involves periods of flares and remission. Treatment includes antimalarials, immunosuppressants, and biologics.

There are currently 5 lupus clinical trials recruiting participants in Jacksonville, FLORIDA. These studies are seeking a combined 1,251 participants. Research is being sponsored by Bristol-Myers Squibb, Novartis Pharmaceuticals, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lupus Clinical Trials in Jacksonville — FAQ

Are there lupus clinical trials in Jacksonville?

Yes, there are 5 lupus clinical trials currently recruiting in Jacksonville, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Jacksonville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Jacksonville research site will contact you about next steps.

Are clinical trials in Jacksonville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Jacksonville studies also compensate for your time and travel.

What lupus treatments are being tested?

The 5 active trials in Jacksonville are testing new therapies including novel drugs, biologics, and treatment approaches for lupus.

Data updated March 2, 2026 from ClinicalTrials.gov